{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:34:52Z","timestamp":1787070892010,"version":"build-2736575974"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>ABSTRACTS<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>To evaluate the outcomes and prognostic factors in patients with brain metastatic renal cell carcinoma (bmRCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The data of 322 patients with metastatic renal cell carcinoma, taken between 2012 and 2020, were retrospectively reviewed. Overall survival (OS) and prognostic factors were evaluated with Kaplan\u2013Meier analysis and Cox regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Forty (12.4%) of the patients had bmRCC. Seventeen (42.5%) of the patients were\n                      <jats:italic toggle=\"yes\">de novo<\/jats:italic>\n                      metastatic, and nine (22.5%) of the patients had brain metastases at presentation. Twenty-four (60%) patients previously had received various therapies (tyrosine kinase inhibitor or checkpoint inhibitors). After brain metastases developed, 35 (87.5%) of the patients received brain radiotherapy (whole-brain radiotherapy or stereotactic radiosurgery), and twenty-five (62.5%) patients received different systemic therapies. Nine patients received sunitinib, nine received pazopanib, five received nivolumab, and two received axitinib. The median OS was 8.8 months (range: 2.9\u201314.6) for all patients with bmRCC. In univariate analysis, the number of brain metastasis (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.35), the site of brain metastasis (left, right or bilateral) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.79), the largest size of brain metastasis (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.45), the number of extracranial metastatic sites (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.81), de novo metastatic disease (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.17), primary tumor site (left or right) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.90), and tumor grade (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.09) were not statistically significant factors on OS. However, age (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02), a history of nephrectomy (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), receiving brain radiotherapy (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.005), and type of systemic treatment (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.04) were statistically significant. Only, the effect of brain radiotherapy on OS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.01) was confirmed in multivariate analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In this study, we observed that the prognosis of patients with bmRCC was poor. Despite a small number of patients, we detected that the effect of tyrosine kinase inhibitors and nivolumab was comparable, and receiving brain radiotherapy was a prognostic factor for OS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_972_22","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T03:03:24Z","timestamp":1708484604000},"page":"S587-S591","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases"],"prefix":"10.4103","volume":"19","author":[{"given":"Izzet","family":"Dogan","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayca","family":"Iribas","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nail","family":"Paksoy","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sezai","family":"Vatansever","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mert","family":"Basaran","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4,29]]},"reference":[{"key":"R1-20241021","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.juro.2008.06.037","article-title":"Renal cell carcinoma in young and old patients--Is there a difference?","volume":"180","author":"Thompson","year":"2008","journal-title":"J Urol"},{"key":"R2-20241021","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1200\/JCO.2005.07.055","article-title":"Prognostic value of histologic subtypes in renal cell carcinoma: A multicenter experience","volume":"23","author":"Patard","year":"2005","journal-title":"J Clin Onco"},{"key":"R3-20241021","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R4-20241021","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): Extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"R5-20241021","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"R6-20241021","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: A population-based study","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro Oncol"},{"key":"R7-20241021","doi-asserted-by":"crossref","first-page":"432","DOI":"10.6004\/jnccn.2020.7634","article-title":"Prognosis of \u0131ncidental brain metastases in patients with advanced renal cell carcinoma","volume":"19","author":"Kotecha","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"R8-20241021","first-page":"6836234","article-title":"Risk factors for brain metastases in patients with renal cell carcinoma","author":"Ke","year":"2020","journal-title":"Biomed Res Int 2020"},{"key":"R9-20241021","doi-asserted-by":"crossref","first-page":"e1163","DOI":"10.1016\/j.clgc.2019.08.006","article-title":"Brain metastasis from renal-cell carcinoma: An \u0131nstitutional study","volume":"17","author":"Suarez-Sarmiento","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"R10-20241021","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.clgc.2018.11.007","article-title":"Improved survival outcomes for kidney cancer patients with brain metastases","volume":"17","author":"Bowman","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"R11-20241021","doi-asserted-by":"crossref","first-page":"100805","DOI":"10.1016\/j.currproblcancer.2021.100805","article-title":"Survival benefit with resection of brain metastases from renal cell carcinoma in the setting of molecular targeted therapy and\/or immune therapy","volume":"46","author":"Huntoon","year":"2021","journal-title":"Curr Probl Cancer"},{"key":"R12-20241021","doi-asserted-by":"crossref","first-page":"e935","DOI":"10.1016\/j.clgc.2018.03.015","article-title":"Utilization of stereotactic radiosurgery for renal cell carcinoma brain metastases","volume":"16","author":"Haque","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"R13-20241021","doi-asserted-by":"crossref","first-page":"182.e9","DOI":"10.1016\/j.urolonc.2018.10.021","article-title":"Renal cell carcinoma and brain metastasis: Questioning the dogma of role for cytoreductive nephrectomy","volume":"37","author":"Daugherty","year":"2019","journal-title":"Urol Oncol"},{"key":"R14-20241021","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s11255-019-02139-9","article-title":"Do renal cell carcinoma patients with brain metastases still need nephrectomy?","volume":"51","author":"Zhuang","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"R15-20241021","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.clgc.2019.02.007","article-title":"Stereotactic radiation therapy for renal cell carcinoma brain metastases in the tyrosine kinase \u0131nhibitors era: Outcomes of 120 patients","volume":"17","author":"Klausner","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"R16-20241021","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.clgc.2019.05.002","article-title":"Cabozantinib in renal cell carcinoma with brain metastases: Safety and efficacy in a real-world population","volume":"17","author":"Peverelli","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"R17-20241021","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1001\/jamaoncol.2021.4544","article-title":"Clinical activity and safety of cabozantinib for brain metastases in patients with renal cell carcinoma","volume":"7","author":"Hirsch","year":"2021","journal-title":"JAMA Oncol"},{"key":"R18-20241021","doi-asserted-by":"crossref","first-page":"100057","DOI":"10.1016\/j.esmoop.2021.100057","article-title":"Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases","volume":"6","author":"Steindl","year":"2021","journal-title":"ESMO Open"},{"key":"R19-20241021","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/cncr.34016","article-title":"Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: Check Mate 920","volume":"128","author":"Emamekhoo","year":"2022","journal-title":"Cancer"},{"key":"R20-20241021","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/JCO.18.02218","article-title":"Safety and efficacy of nivolumab in brain metastases from renal cell carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study","volume":"37","author":"Flippot","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_972_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:38:26Z","timestamp":1787067506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_972_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":20,"journal-issue":{"issue":"Suppl 2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_972_22","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"2022-05-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}